At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Ketamine 4 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head and Neck Cancer
In Brief
A Phase 2 clinical trial evaluating Ketamine and Placebo for Mucositis and Head and Neck Cancer. Completed, enrolled 11 participants across 1 site.
Detailed Summary
* The primary objective is to determine the reduction in pain score by ketamine mouthwash compared to placebo in head and neck cancer patients with refractory mucositis. * The secondary objectives are to describe the duration of analgesia and adverse effects associated with ketamine and placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMucositis, Head and Neck Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJul 2012
Primary CompletionAug 2016
TodayJul 2026
First PostedJul 31, 2012
Enrollment StartJun 1, 2010
Primary CompletionAug 16, 2016
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 13.9 years ago
Interventions
Ketaminedrug
Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
Placebodrug